Press Releases

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 16, 2022
WATERTOWN, Mass. , March 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank
Mar 09, 2022
New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savings WATERTOWN, Mass. , March 09, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to
EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer
Mar 07, 2022
WATERTOWN, Mass. , March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Isabelle
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments
Mar 03, 2022
– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022 , continuing positive safety and efficacy profile seen at six-month readout                –  Phase 2 trials for EYP-1901 in wet AMD and NPDR are
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference
Mar 01, 2022
WATERTOWN, Mass. , March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker , Chief Executive
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
Feb 24, 2022
WATERTOWN, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live
EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
Feb 12, 2022
- Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up - 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901 - Positive safety data continued with no dose limiting toxicities, no
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements
Jan 10, 2022
– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in wet AMD expected to initiate in Q3
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
Jan 10, 2022
WATERTOWN, Mass. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C.
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
Dec 07, 2021
ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint’s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all markets WATERTOWN, Mass.
EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering
Nov 19, 2021
WATERTOWN, Mass. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously
EyePoint Pharmaceuticals Announces Pricing of Public Offering
Nov 16, 2021
WATERTOWN, Mass. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 16, 2021
WATERTOWN, Mass. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has commenced an
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
Nov 13, 2021
- Interim six-month results show positive safety data, no dose limiting toxicities, no ocular serious adverse events (SAEs), and no drug-related systemic SAEs - 76% and 53% of patients were rescue-free up to four and six months, respectively, following a single injection of EYP-1901 - Stable best
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Nov 11, 2021
WATERTOWN, Mass. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that Nancy Lurker , Chief Executive
EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
Nov 05, 2021
WATERTOWN, Mass. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that management will host a conference
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Nov 03, 2021
– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) – – Topline data for DAVIO trial to be presented at American Academy of Ophthalmology (AAO) 2021 Annual Meeting on November 13, 2021 - –
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer
Nov 01, 2021
WATERTOWN, Mass. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S.
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
Oct 27, 2021
WATERTOWN, Mass. , Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live
EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
Oct 12, 2021
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ ® CALM registry study collecting real-world data on patients with fluocinolone acetonide intravitreal (FAi) implant 0.18 mg is ongoing – WATERTOWN, Mass. , Oct.
Displaying 21 - 40 of 457